Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial

被引:0
|
作者
Jacewicz, Maciej [1 ,3 ]
Guenzel, Karsten [4 ]
Rud, Erik [2 ]
Sandbaek, Gunnar [2 ,3 ]
Magheli, Ahmed [4 ]
Busch, Jonas [4 ]
Hinz, Stefan [5 ]
Baco, Eduard [1 ,3 ]
机构
[1] Oslo Univ Hosp, Dept Urol, N-0586 Oslo, Norway
[2] Oslo Univ Hosp, Dept Radiol, Oslo, Norway
[3] Univ Oslo, Oslo, Norway
[4] Vivantes Klinikum Urban, Dept Urol, Berlin, Germany
[5] Univ Klinikum Magdeburg, Dept Urol, Magdeburg, Germany
来源
LANCET INFECTIOUS DISEASES | 2022年 / 22卷 / 10期
关键词
CANCER; COMPLICATIONS; SEPSIS; CONSENSUS; RATES;
D O I
10.1016/S1473-3099(22)00373
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background The benefit of antibiotic prophylaxis is uncertain when performing transperineal prostate biopsies. Judicious use of antibiotics is required as antimicrobial resistance increases worldwide. We aimed to assess whether antibiotic prophylaxis can be omitted when performing transperineal prostate biopsies under local anaesthesia as an outpatient procedure. Methods In this randomised, open-label, non-inferiority trial, we aimed to enrol all patients with a suspicion of prostate cancer undergoing transperineal prostate biopsies at two hospitals in Norway and Germany. Patients with a high risk of infection or ongoing infection were excluded. Patients were randomised (1:1) to receive intramuscular (in Norway) or intravenous (in Germany) 1 center dot 5 g cefuroxime antibiotic prophylaxis or not. Follow-up assessments were done after 2 weeks and 2 months. The primary outcome was rate of sepsis or urinary tract infections requiring hospitalisation within 2 months. The secondary outcome was the rate of urinary tract infections not requiring hospitalisation. These outcomes were assessed in all eligible randomly allocated participants with a prespecified non-inferiority margin of 4%. Biopsies were performed using an MRI-transrectal ultrasound fusion transperineal technique under local anaesthesia. Patients with a positive MRI underwent 2-4 biopsies per target; in addition, 8-12 systematic biopsies were performed in biopsy naive and MRI-negative patients. This study is registered with ClinicalTrials.gov, NCT04146142. Findings Between Nov 11, 2019, and Feb 23, 2021, 792 patients were referred for biopsy, of whom 555 (70%) were randomly allocated to treatment groups. 277 (50%) patients received antibiotic prophylaxis and 276 (50%) did not; two (<1%) patients were excluded after randomisation because of unknown allergy to study drug. Sepsis or urinary tract infections requiring hospitalisation occurred in no patients given antibiotic prophylaxis (0%, 95% CI 0 to 1 center dot 37) or not given antibiotic prophylaxis (0%, 0 to 1 center dot 37; difference 0% [95% CI -1 center dot 37 to 1 center dot 37]). Urinary tract infections not requiring hospitalisation occurred in one patient given antibiotic prophylaxis (0 center dot 36%, 95% CI 0 center dot 01 to 2 center dot 00) and three patients not given antibiotic prophylaxis (1 center dot 09%, 0 center dot 37 to 3 center dot 15; difference 0 center dot 73% [95% CI -1 center dot 08 to 2 center dot 81]). The number needed to treat with antibiotic prophylaxis to avoid one infection was 137. Interpretation The non-inferiority margin of 4% was not exceeded, suggesting rates of infections were not higher in patients not receiving antibiotic prophylaxis before transperineal prostate biopsy than in those receiving it. Therefore, antibiotic prophylaxis might be omitted in this population. Copyright (c) 2022 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1465 / 1471
页数:7
相关论文
共 50 条
  • [41] Antibiotic prophylaxis and complications following prostate biopsies - a systematic review
    Klemann, Nina
    Helgstrand, John Thomas
    Brasso, Klaus
    Vainer, Ben
    Iversen, Peter
    Roder, Martin Andreas
    DANISH MEDICAL JOURNAL, 2017, 64 (01):
  • [42] Oral Nystatin Versus Intravenous Fluconazole as Neonatal Antifungal Prophylaxis: Non-inferiority Trial
    Mersal, Ali
    Alzahrani, Ibrahim
    Azzouz, Mahasen
    Alsubhi, Adel
    Alsawaigh, Heba
    Albshri, Nouf
    Bajammal, Manal
    Avand, Ghazal
    Almahbosh, Abdulmajid
    JOURNAL OF CLINICAL NEONATOLOGY, 2013, 2 (02) : 87 - 91
  • [43] Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial
    Jan-Erik Johansson
    John Bratel
    Mats Hardling
    Lena Heikki
    Ulf-Henrik Mellqvist
    Bengt Hasséus
    Bone Marrow Transplantation, 2019, 54 : 1482 - 1488
  • [44] Cryotherapy as prophylaxis against oral mucositis after high-dose melphalan and autologous stem cell transplantation for myeloma: a randomised, open-label, phase 3, non-inferiority trial
    Johansson, Jan-Erik
    Bratel, John
    Hardling, Mats
    Heikki, Lena
    Mellqvist, Ulf-Henrik
    Hasseus, Bengt
    BONE MARROW TRANSPLANTATION, 2019, 54 (09) : 1482 - 1488
  • [45] Reduced versus maximum tolerated methotrexate dose concomitant with adalimumab in patients with rheumatoid arthritis (MIRACLE): a randomised, open-label, non-inferiority trial
    Tamai, Hiroya
    Ikeda, Kei
    Miyamoto, Toshiaki
    Taguchi, Hiroaki
    Kuo, Chang-Fu
    Shin, Kichul
    Hirata, Shintaro
    Okano, Yutaka
    Sato, Shinji
    Yasuoka, Hidekata
    Kuwana, Masataka
    Ishii, Tomonori
    Kameda, Hideto
    Kojima, Toshihisa
    Taninaga, Takehiro
    Mori, Masahiko
    Miyagishi, Hideaki
    Sato, Yasunori
    Tsai, Wen-Chan
    Takeuchi, Tsutomu
    Kaneko, Yuko
    LANCET RHEUMATOLOGY, 2023, 5 (04): : 215 - 224
  • [46] Dihydroartemisinin-piperaquine versus artesunate-amodiaquine for treatment of malaria infection in pregnancy in Ghana: an open-label, randomised, non-inferiority trial
    Osarfo, Joseph
    Tagbor, Harry
    Cairns, Matthew
    Alifrangis, Michael
    Magnussen, Pascal
    TROPICAL MEDICINE & INTERNATIONAL HEALTH, 2017, 22 (08) : 1043 - 1052
  • [47] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Cochereau, D.
    Lecuru, F.
    ONCOLOGIE, 2015, 17 (11-12) : 595 - 596
  • [48] Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
    Kehoe, Sean
    Hook, Jane
    Nankivell, Matthew
    Jayson, Gordon C.
    Kitchener, Henry
    Lopes, Tito
    Luesley, David
    Perren, Timothy
    Bannoo, Selina
    Mascarenhas, Monica
    Dobbs, Stephen
    Essapen, Sharadah
    Twigg, Jeremy
    Herod, Jonathan
    McCluggage, Glenn
    Parmar, Mahesh
    Swart, Ann-Marie
    LANCET, 2015, 386 (9990): : 249 - 257
  • [49] Thrombectomy alone versus intravenous alteplase plus thrombectomy in patients with stroke: an open-label blinded-outcome, randomised non-inferiority trial
    Fischer, Urs
    Kaesmacher, Johannes
    Strbian, Daniel
    Eker, Omer
    Cognard, Christoph
    Plattner, Patricia S.
    Butikofer, Lukas
    Mordasini, Pasquale
    Deppeler, Sandro
    Pereira, Vitor M.
    Albucher, Jean Francois
    Darcourt, Jean
    Bourcier, Romain
    Benoit, Guillon
    Papagiannaki, Chrysanthi
    Ozkul-Wermester, Ozlem
    Sibolt, Gerli
    Tiainen, Marjaana
    Gory, Benjamin
    Richard, Sebastien
    Liman, Jan
    Ernst, Marielle Sophie
    Boulanger, Marion
    Barbier, Charlotte
    Mechtouff, Laura
    Zhang, Liqun
    Marnat, Gaultier
    Sibon, Igor
    Nikoubashman, Omid
    Reich, Arno
    Consoli, Arturo
    Lapergue, Bertrand
    Ribo, Marc
    Tomasello, Alejandro
    Saleme, Suzana
    Macian, Francisco
    Moulin, Solne
    Pagano, Paolo
    Saliou, Guillaume
    Carrera, Emmanuel
    Janot, Kevin
    Hernandez-Perez, Maria
    Pop, Raoul
    Della Schiava, Lucie
    Luft, Andreas R.
    Piotin, Michel
    Gentric, Jean Christophe
    Pikula, Aleksandra
    Pfeilschifter, Waltraud
    Arnold, Marcel
    LANCET, 2022, 400 (10346): : 104 - 115
  • [50] Cloxacillin versus pristinamycin for superficial pyodermas: A randomized, open-label, non-inferiority study
    Chosidow, O
    Bernard, P
    Berbis, P
    Humbert, P
    Crickx, B
    Jarlier, V
    DERMATOLOGY, 2005, 210 (04) : 370 - 374